

MayoComplete Bladder and Prostate Cancer Panel, Next-Generation Sequencing, Tumor

Overview

Useful For

Primarily for determining if patients will respond to targeted therapy

Assessment of microsatellite instability for immunotherapy decisions

Genetics Test Information

This test uses targeted next-generation sequencing to determine microsatellite instability (MSI) status and evaluate for somatic mutations within the APC, AR, ARID1A, ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CDK12, CDKN2A, CHD1, CHEK1, CHEK2, CTNNB1, EGFR, ERBB2, ERCC2, FANCA, FANCC, FANCL, FGFR1, FGFR2, FGFR3, FOXA1, MLH1, MSH2, MSH6, PALB2, PMS2, PTEN, RAD51B, RAD51C, RAD51D, RAD54L, RB1, SPOP, TERT, and TP53 genes. See Targeted Genes and Methodology Details for MayoComplete Bladder and Prostate Cancer Panel for details regarding the targeted gene regions evaluated by this test.

This test is performed to evaluate for somatic mutations within solid tumor samples. This test **does not assess** for germline alterations within the genes listed.

Additional Tests

Test Id	Reporting Name	Available Separately	Always Performed
SLIRV	Slide Review in MG	No, (Bill Only)	Yes

Testing Algorithm

When this test is ordered, slide review will always be performed at an additional charge.

Special Instructions

- Tissue Requirements for Solid Tumor Next-Generation Sequencing
- Targeted Genes and Methodology Details for MayoComplete Bladder/Prostate Panel

Highlights

This panel, performed on formalin-fixed, paraffin-embedded tumor or cytology slides, includes a curated list of 39 genes important for the clinical management of patients with prostate or bladder cancer.

It identifies alterations in the *FGFR* genes that may predict response to targeted therapies and DNA damage response genes associated with therapeutic eligibility to poly(adenosine diphosphate-ribose) polymerase inhibitors.

This test evaluates mismatch repair genes and microsatellite instability (MSI) status (MSS, MSI-H) as this is often clinically actionable for determining the efficacy of immunotherapy in solid tumors.

Method Name

Sequence Capture and Targeted Next-Generation Sequencing (NGS)



MayoComplete Bladder and Prostate Cancer Panel, Next-Generation Sequencing, Tumor

NY State Available

Yes

Specimen

Specimen Type

Varies

Ordering Guidance

Multiple oncology (cancer) gene panels are available. For more information see <u>Hematology, Oncology, and Hereditary</u> Test Selection Guide.

Necessary Information

- 1. A pathology report (final or preliminary) is required and must accompany specimen for testing to be performed.
- 2. The following information must be included in the report provided.
- -Patient name
- -Block number-must be on all blocks, slides and paperwork (can be handwritten on the paperwork)
- -Date of tissue collection
- -Source of the tissue

Specimen Required

This assay requires at least 20% tumor nuclei.

- -Preferred amount of tumor area with sufficient percent tumor nuclei: tissue 216 mm(2)
- -Minimum amount of tumor area: tissue 36 mm(2)
- -These amounts are cumulative over up to 10 unstained slides and must have adequate percent tumor nuclei.
- -Tissue fixation: 10% neutral buffered formalin, not decalcified
- -For specimen preparation guidance, see <u>Tissue Requirement for Solid Tumor Next-Generation Sequencing</u>. In this document, the sizes are given as 4 mm x 4 mm x 10 slides as preferred: approximate/equivalent to 144 mm(2) and the minimum as 3 mm x 1 mm x 10 slides: approximate/equivalent to 36 mm(2).

Preferred: Submit 3, if available, or 2 of the following specimens. **Acceptable:** Submit **at least one** of the following specimens.

Specimen Type: Tissue block

Collection Instructions: Submit a formalin-fixed, paraffin-embedded tissue block with acceptable amount of tumor

tissue.

Specimen Type: Tissue slide

Slides: 1 Hematoxylin and eosin-stained and 10 unstained

Collection Instructions: Submit the followings slides:



MayoComplete Bladder and Prostate Cancer Panel, Next-Generation Sequencing, Tumor

1 Slide stained with hematoxylin and eosin

AND

10 Unstained, nonbaked slides with 5-micron thick sections of the tumor tissue.

Note: The total amount of required tumor nuclei can be obtained by scraping up to 10 slides from the same block.

Additional Information: Unused unstained slides will not be returned.

Specimen Type: Cytology slide (direct smears or ThinPrep)

Slides: 1 to 3 Slides

Collection Instructions: Submit 1 to 3 slides stained and coverslipped with a total of 5000 nucleated cells (preferred), or

at least 3000 nucleated cells (minimum).

Note: Glass coverslips are preferred; plastic coverslips are acceptable but will result in longer turnaround times.

Additional Information: Cytology slides will not be returned.

Forms

If not ordering electronically, complete, print, and send an Oncology Test Request (T729) with the specimen.

Specimen Minimum Volume

See Specimen Required

Reject Due To

All specimens will be evaluated at Mayo Clinic Laboratories for test suitability

Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
Varies	Ambient (preferred)		
	Refrigerated		

Clinical & Interpretive

Clinical Information

Molecular genetic profiling is often needed to identify targets amenable to targeted therapies and to minimize treatment costs and therapy-associated risks. Microsatellite instability (MSI) status is an increasingly important biomarker for determining effective immunotherapeutic treatment options for patients with solid tumors.

This test uses formalin-fixed paraffin-embedded tissue or cytology slides to assess for somatic mutations involving the following genes known to be associated with bladder/prostate cancer: APC, AR, ARID1A, ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CDK12, CDKN2A, CHD1, CHEK1, CHEK2, CTNNB1, EGFR, ERBB2, ERCC2, FANCA, FANCC, FANCL, FGFR1, FGFR2, FGFR3, FOXA1, MLH1, MSH2, MSH6, PALB2, PMS2, PTEN, RAD51B, RAD51C, RAD51D, RAD54L, RB1, SPOP, TERT, and TP53. The results of this test can be useful for assessing prognosis and guiding treatment of individuals with bladder/prostate tumors. The data can also be used to help determine clinical trial eligibility for patients with alterations in genes not amenable to current US Food and Drug Administration-approved targeted therapies.

Reference Values



MayoComplete Bladder and Prostate Cancer Panel, Next-Generation Sequencing, Tumor

An interpretive report will be provided.

Interpretation

The interpretation of molecular biomarker analysis includes an overview of the results and the associated diagnostic, prognostic, and therapeutic implications.

Cautions

This test cannot differentiate between somatic and germline alterations. Additional testing may be necessary to clarify the significance of results if there is a potential hereditary risk.

DNA variants of uncertain significance may be identified.

A negative result does not rule out the presence of a variant that may be present below the limits of detection of this assay. In a specimen with 20% or more tumor content, the analytical sensitivity of this assay for sequence reportable alterations is 5% mutant allele frequency with a minimum coverage of 500X.

Point mutations and small deletion-insertion mutations (delins) will be detected in the APC, AR, ARID1A, ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CDK12, CDKN2A, CHD1, CHEK1, CHEK2, CTNNB1, EGFR, ERBB2, ERCC2, FANCA, FANCC, FANCL, FGFR1, FGFR2, FGFR3, FOXA1, MLH1, MSH2, MSH6, PALB2, PMS2, PTEN, RAD51B, RAD51C, RAD51D, RAD54L, RB1, SPOP, TERT (5'UTR), and TP53 genes only. This test may detect single exon deletions but does not detect multi-exon deletions, duplications, larger-scale genomic copy number variants, copy neutral loss of heterozygosity (LOH), or epigenetic modifications such as promoter methylation. Delins of 1,000 bp or less are detectable with at least 50 or more supporting reads.

This test cannot reliably determine if a variant identified in *PMS2* exons 11-15 originated from *PMS2* or the highly homologous pseudogene *PMS2CL*. In the instance that a reportable variant is detected in *PMS2* exons 11-15, additional testing will be recommended in the patient report.

Variant allele frequency (VAF) is the percentage of sequencing reads supporting a specific variant divided by the total sequencing reads at that position. In somatic testing, VAF should be interpreted in the context of several factors including but not limited to: tumor purity/heterogeneity/copy number status (ploidy, gains/losses, loss of heterozygosity) and sequencing artifact/misalignment.(1,2)

Rare alterations (ie, polymorphisms) may be present that could lead to false-negative or false-positive results.

The presence or absence of a variant may not be predictive of response to therapy in all patients.

Test results should be interpreted in the context of clinical, tumor sampling, histopathological, and other laboratory data. If results obtained do not match other clinical or laboratory findings, contact the laboratory for discussion. Misinterpretation of results may occur if the information provided is inaccurate or incomplete.

Reliable results are dependent on adequate specimen collection and processing. This test has been validated on cytology slides and formalin-fixed, paraffin-embedded tissues; other types of fixatives are discouraged. Improper treatment of tissues, such as decalcification, may cause polymerase chain reaction failure.



MayoComplete Bladder and Prostate Cancer Panel, Next-Generation Sequencing, Tumor

Supportive Data

Performance Characteristics:

The limit of detection for calling a somatic variant (single nucleotide variants [SNV] and deletions/insertions [delins, formerly indel]) is 5% variant allele frequency (VAF) and having at least 500x deduplicated coverage.

Verification studies demonstrated concordance between this test and the reference method for detection of SNV and delins is 98.5% (673/683) and 98.4% (122/124) of variants, respectively. Concordance for the detection of delins was 99.0% (100/101) in variants 1 to 10 base pairs (bp) in size, 93.3% (14/15) in variants 11 to 50 bp in size, and 100% (8/8) in variants over 50 bp in size.

Microsatellite instability (MSI) evaluation is accurate at a tumor purity of at least 10% for colorectal tumors and 20% for other tumor types. During verification studies, 98% (200/204) concordance for MSI status was observed between this test and the reference method.

To ensure accuracy, this test will be performed on cases that are estimated by a pathologist to have at least 20% tumor cells.

Clinical Reference

- 1. Strom SP. Current practices and guidelines for clinical next-generation sequencing oncology testing. Cancer Biol Med. 2016;13(1):3-11. doi:10.28092/j.issn.2095-3941.2016.0004
- 2. Spurr L, Li M, Alomran N, et al. Systematic pan-cancer analysis of somatic allele frequency. Sci Rep. 2018;8(1):7735. Published 2018 May 16. doi:10.1038/s41598-018-25462-0
- 3. Abida W, Armenia J, Gopalan A, et al. Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. JCO Precis Oncol. 2017;2017:PO.17.00029
- 4. Robertson AG, Kim J, Al-Ahmadie H, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171(3):540-556.e25
- 5. Siefker-Radtke AO, Necchi A, Park SH, et al. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study. Lancet Oncol. 2022;23(2):248-258
- 6. Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA Approval Summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. 2019;25(13):3753-3758

Performance

Method Description

Next-generation sequencing is performed to determine microsatellite instability (MSI) status and evaluate the presence of a mutation in most coding regions of the APC, AR, ARID1A, ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CDK12, CDKN2A, CHD1, CHEK1, CHEK2, CTNNB1, EGFR, ERBB2, ERCC2, FANCA, FANCC, FANCL, FGFR1, FGFR2, FGFR3, FOXA1, MLH1, MSH2, MSH6, PALB2, PMS2, PTEN, RAD51B, RAD51C, RAD51D, RAD54L, RB1, SPOP, TERT, and TP53 genes. See Targeted Genes and Methodology Details for MayoComplete Bladder and Prostate Cancer Panel for details regarding the targeted gene regions identified by this test.(Unpublished Mayo method)

A pathology review and macro dissection to enrich for tumor cells is performed prior to slide scraping.



MayoComplete Bladder and Prostate Cancer Panel, Next-Generation Sequencing, Tumor

PDF Report

No

Day(s) Performed

Monday through Friday

Report Available

12 to 20 days

Specimen Retention Time

Tissue blocks: Unused portions of blocks will be returned; Tissue slides: Unused slides are stored for at least 5 years; Extracted DNA: 3 months

Performing Laboratory Location

Mayo Clinic Laboratories - Rochester Main Campus

Fees & Codes

Fees

- Authorized users can sign in to <u>Test Prices</u> for detailed fee information.
- Clients without access to Test Prices can contact <u>Customer Service</u> 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact <u>Customer Service</u>.

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

88381-Microdissection, manual 81457

LOINC® Information

Test ID	Test Order Name	Order LOINC® Value
MCBPP	MayoComplete Bladder/Prostate	105589-6
	Panel	

Result ID	Test Result Name	Result LOINC® Value
619605	Result	82939-0
619606	Interpretation	69047-9
619607	Additional Information	48767-8
619608	Specimen	31208-2



MayoComplete Bladder and Prostate Cancer Panel, Next-Generation Sequencing, Tumor

619609	Tissue ID	80398-1
619610	Method	85069-3
619611	Disclaimer	62364-5
619612	Released By	18771-6